NVCR NovoCure Ltd

NEUTRAL Impact: 3/10 DEFA14A
Horizon weeks Filed Apr 20, 2026 Processed 1mo ago SEC 0001645113-26-000034
Proxy solicitation materials
Latest settled — T+20d
NVCR ▲ +42.76% at T+20d
NEUTRAL call ✓ call won +42.76% · α vs SPY +37.85% · entry $12.23 → $17.46
Next anchor: T+60d in 5w
Currently $17.24 · +40.96% from $12.23 entry
Entry anchored
Apr 20, 03:59 PM ET
via Databento tick
T+1d
+6.46%
call +6.46% · α +5.44%
$13.02
settled 7w ago
T+5d
-0.90%
call -0.90% · α -1.98%
$12.12
settled 6w ago
T+20d
+42.76%
call +42.76% · α +37.85%
$17.46
settled 23d ago
T+60d
call — · α —
in 5w

Price Chart

Loading chart...

Executive Summary

NovoCure's DEFA14A filing is a definitive proxy statement for its 2026 Annual Meeting, where shareholders will vote on director elections, auditor ratification, executive compensation, and an amended incentive plan. This follows recent board changes, suggesting the vote is routine. The filing is neutral with low impact.

Actionable Insight

This is a routine annual proxy filing. Monitor for any unexpected outcomes in the shareholder vote, though none are anticipated given the lack of dissident activity. The recent executive compensation change noted in the 8-K is the only notable event.

Key Facts

  • Filing is a definitive proxy statement (DEFA14A) for the 2026 Annual Meeting.
  • Shareholders will vote on 11 director nominees, auditor ratification, executive compensation, and an amended incentive plan.
  • Recent 8-K filing (11 days prior) reported a compensation change for an executive officer.
  • No activist campaign or dissident slate is present; this is a management solicitation.

Financial Impact

No direct financial impact from the proxy filing itself.

executive compensationgovernance

Risk Factors

  • Low risk of shareholder revolt on any proposal, as is typical for routine management solicitations.
  • Potential for minor governance concerns if any director nominee faces significant opposition, though none is indicated.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001645113-26-000034
Document: 0001645113-26-000034-index-headers.html0001645113-26-000034
Document: 0001645113-26-000034-index.html0001645113-26-000034
Document: 0001645113-26-000034.txt0001645113-26-000034
9 reports for NVCR
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for NVCR — sortable, filterable
Type Now
Jun 5, 2026
4d ago
8-K
NEUTRAL ★ 4/10
$17.17 awaiting T+1awaiting T+1$17.24 (+0.41%)
Jun 3, 2026
6d ago
Insider Cluster
NEUTRAL ★ 2/10
$17.99 $17.16▼ −4.61%▼ −2.04%$17.24 (−4.17%)
Jun 3, 2026
6d ago
Insider Cluster
NEUTRAL ★ 2/10
$17.99 $17.16▼ −4.61%▼ −2.02%$17.24 (−4.17%)
Apr 20, 2026
7w ago
DEFA14A
NEUTRAL ★ 3/10
$12.23 $13.02▲ +6.46%▲ +5.44%$17.24 (+40.96%)
Feb 27, 2026
14w ago
Insider Cluster
NEUTRAL ★ 4/10
$13.67 $13.52▼ −1.10%▼ −1.15%$17.24 (+26.12%)
Feb 27, 2026
14w ago
Insider Cluster
BEARISH ★ 5/10
$13.67 $13.52▲ +1.10%▲ +1.15%$17.24 (−26.12%)
Feb 27, 2026
14w ago
Insider Cluster
NEUTRAL ★ 3/10
$13.67 $13.52▼ −1.10%▼ −1.15%$17.24 (+26.12%)
Feb 26, 2026
14w ago
8-K
MIXED ★ 7/10
$13.75 $13.67▼ −0.58%▼ −0.13%$17.24 (+25.38%)
Feb 24, 2026
15w ago
8-K
NEUTRAL ★ 5/10
$14.99 $13.75▼ −8.27%▼ −7.73%$17.24 (+15.01%)
Showing 9 of 9

US Market Status

Market Closed — Opens Thu (10h 56m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access